How Some Prostate Cancers Transform into a More Aggressive Type Has Been Discovered

Anti-androgen (hormone-suppressing) treatments have revolutionized prostate cancer treatment. However, some men receiving these targeted therapies develop resistance, and their prostate cancer cells acquire neuroendocrine characteristics . No effective treatment exists for neuroendocrine prostate cancer (NEPC). In February 2019, Cancer Cell published a study discovering how prostate cancer acquires aggressive neuroendocrine features. Changes in metabolic processes and epigenetic mechanisms make prostate cancer resistant to treatment.
Related Topic:
Prostate cancer ranks second in cancer-related deaths among men. Prostate cancer cells grow using androgen (male) hormones such as testosterone. Abiraterone and enzalutamide are targeted treatments that block these hormones and have prolonged survival for many patients. However, nearly all men with advanced prostate cancer receiving these treatments develop treatment resistance . Prostate cancer cells remodel the tumor microenvironment and develop various strategies to resist treatment. In this newly published study, metastatic neuroendocrine prostate cancer (NEPC) tissue samples from men, prostate cancer cells, and NEPC mouse models were analyzed.
According to the Research Results;
- In NEPC cells, Protein Kinase C lambda/iota (PKCλ/ι) activity was observed to decline. Protein kinase C is an important tumor suppressor gene. Reduced activity of this gene enables cancer to acquire aggressive characteristics.
- NEPC cells increase synthesis of the metabolite serine . Serine is one of the nonessential (non-basic) amino acids. Therefore, blocking serine synthesis may be an effective cancer treatment strategy with few adverse effects.
- NEPC cells also increase serine synthesis through the cellular pathway mTORC1/ATF4. This enables proper lysosome positioning and epigenetic regulation.
Below, the study’s graphical summary can be seen:

What Does This Study Mean for Us?
- In neuroendocrine prostate cancer, prostate cancer cells acquire entirely different characteristics. They even change the targeted androgen receptors , so current targeted treatments provide no benefit.
- This study is important for identifying the mechanism transforming prostate cancer into a neuroendocrine form. The findings may enable new generations of effective treatment.
- The research also noted that, in 2010, for the hematological condition myelodysplastic syndrome, FDA approval was granted to decitabine, which may also be effective for NEPC. This remains experimental. In clinical trials , its effectiveness must be demonstrated. Decitabine has hypomethylating properties and targets epigenetic mechanisms.
Sources
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.
Cancer Cell, 28 February 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.